Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

2014 ◽  
Vol 15 (12) ◽  
pp. 1397-1406 ◽  
Author(s):  
Peter Hoskin ◽  
Oliver Sartor ◽  
Joe M O'Sullivan ◽  
Dag Clement Johannessen ◽  
Svein I Helle ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Subgroup Analysis ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Double Blind ◽  
Castration Resistant ◽  
Radium 223

scholarly journals Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases

2018 ◽  
pp. 78-82
Author(s):  
A. D. Kaprin ◽  
A. A. Kostin ◽  
N. V. Vorobyev ◽  
S. V. Popov
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Good Tolerability ◽  
Development Of Resistance ◽  
Castration Resistant ◽  
Radium 223 ◽  
Visceral Metastases ◽  
Bone Complications

The development of resistance to endocrine therapy and the tumor progression in patients with prostate cancer are associated with an unfavourable prognosis. The article presents a review of clinical trials of efficacy and safety, as well as the experience in using radioisotope radium-223 chloride in clinical practice in patients with castration-resistant prostate cancer with bone metastases without visceral metastases. It was shown that radium-223 chloride therapy in this category of patients leads to an increase in overall survival and time to the development of bone complications, and is characterized by good tolerability.

Sign in / Sign up

Export Citation Format

Share Document